RAS: Past, Present, and Future

1. A brief history of RAS and the RAS Initiative<br>Frank McCormick<br>2. Not all RAS mutations are equal: A detailed review of the functional diversity of RAS hot spot mutations<br>Rachel A. Burge and G. Aaron Hobbs<br>3. Drug targeting opportunities en route to Ras nanoclusters<br>Karolina Pavic, Rohan Chippalkatti, and Daniel Abankwa<br>4. Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer<br>J. Nathaniel Diehl, Priya S. Hibshman, Irem Ozkan-Dagliyan, Craig M. Goodwin, Sarah V. Howard, Adrienne D. Cox, and Channing J. Der<br>5. Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone<br>Alexander B. Coley, Antonio Ward, Adam B. Keeton, Xi Chen, Yulia Maxuitenko, Aishwarya Prakash, Feng Li, Jeremy B. Foote, Donald J. Buchsbaum, and Gary A. Piazza<br>6. Targeting RAS oncogenesis with SOS1 inhibitors<br>Roman Christian Hillig and Benjamin Bader<br>7. Inhibition of SHP2 as an approach to block RAS-driven cancers<br>Yu-Ting Chou and Trever G. Bivona<br>8. Targeting the “undruggable” RAS with biologics<br>Michael Whaby, Imran Khan, and John P. O'Bryan<br>9. Unraveling and targeting RAS-driven metabolic signaling for therapeutic gain<br>Jonathan M. DeLiberty, Ryan Robb, Claire E. Gates, and Kirsten L. Bryant<br>10. The RASopathies: Biology, genetics and therapeutic options<br>Jody Fromm Longo and Steven L. Carroll<br>